Falah Almohanna

1.6k total citations
49 papers, 1.1k citations indexed

About

Falah Almohanna is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Falah Almohanna has authored 49 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Molecular Biology, 22 papers in Oncology and 7 papers in Immunology. Recurrent topics in Falah Almohanna's work include Cancer Cells and Metastasis (15 papers), Thyroid Cancer Diagnosis and Treatment (4 papers) and Cytokine Signaling Pathways and Interactions (3 papers). Falah Almohanna is often cited by papers focused on Cancer Cells and Metastasis (15 papers), Thyroid Cancer Diagnosis and Treatment (4 papers) and Cytokine Signaling Pathways and Interactions (3 papers). Falah Almohanna collaborates with scholars based in Saudi Arabia, Egypt and United States. Falah Almohanna's co-authors include Hazem Ghebeh, Monther Al‐Alwan, Abdelilah Aboussekhra, Fatmah A. Mansour, Futwan Al‐Mohanna, Asma Tulbah, Dilek Çolak, Abderrezak Bouchama, Ayodele Alaiya and Olfat Al‐Harazi and has published in prestigious journals such as Molecular and Cellular Biology, Scientific Reports and Arteriosclerosis Thrombosis and Vascular Biology.

In The Last Decade

Falah Almohanna

44 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Falah Almohanna Saudi Arabia 18 470 457 201 199 172 49 1.1k
Annalisa Camporeale Italy 21 617 1.3× 389 0.9× 466 2.3× 183 0.9× 107 0.6× 28 1.4k
Roberta Giuliani Italy 16 590 1.3× 185 0.4× 102 0.5× 130 0.7× 129 0.8× 25 1.1k
Orr Sharpe United States 19 497 1.1× 182 0.4× 354 1.8× 219 1.1× 71 0.4× 25 1.5k
Dai Katayose Japan 20 720 1.5× 539 1.2× 96 0.5× 180 0.9× 121 0.7× 24 1.2k
Zhentao Yang China 12 1.0k 2.2× 208 0.5× 436 2.2× 195 1.0× 81 0.5× 26 1.4k
Chi Sun China 20 461 1.0× 194 0.4× 186 0.9× 164 0.8× 68 0.4× 80 1.2k
Nhat‐Tu Le United States 16 480 1.0× 135 0.3× 201 1.0× 114 0.6× 71 0.4× 22 838
Jeremy A. Meier United States 15 541 1.2× 385 0.8× 327 1.6× 185 0.9× 64 0.4× 24 1.1k
Geraldine Gueron Argentina 17 621 1.3× 134 0.3× 109 0.5× 206 1.0× 24 0.1× 38 896
Tracy L. Deem United States 12 484 1.0× 87 0.2× 436 2.2× 101 0.5× 162 0.9× 13 1.1k

Countries citing papers authored by Falah Almohanna

Since Specialization
Citations

This map shows the geographic impact of Falah Almohanna's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Falah Almohanna with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Falah Almohanna more than expected).

Fields of papers citing papers by Falah Almohanna

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Falah Almohanna. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Falah Almohanna. The network helps show where Falah Almohanna may publish in the future.

Co-authorship network of co-authors of Falah Almohanna

This figure shows the co-authorship network connecting the top 25 collaborators of Falah Almohanna. A scholar is included among the top collaborators of Falah Almohanna based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Falah Almohanna. Falah Almohanna is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Chapple, Christopher R., Raouf Seyam, Anthony J. Bullock, et al.. (2024). Development of a Clinically Relevant Preclinical Animal Model to Mimic Suburethral Implantation of Support Materials for Stress Urinary Incontinence. Neurourology and Urodynamics. 44(2). 489–495.
3.
Çolak, Dilek, et al.. (2024). Endogenous osteoprotegerin (OPG) represses ERα and promotes stemness and chemoresistance in breast cancer cells. Cell Death Discovery. 10(1). 377–377. 2 indexed citations
4.
5.
Islam, Syed S., et al.. (2024). Ovarian tumor cell-derived JAGGED2 promotes omental metastasis through stimulating the Notch signaling pathway in the mesothelial cells. Cell Death and Disease. 15(4). 247–247. 3 indexed citations
6.
Pratheeshkumar, Poyil, Abdul K. Siraj, Sandeep Kumar Parvathareddy, et al.. (2023). Overexpression of the pro‐protein convertase furin predicts prognosis and promotes papillary thyroid carcinoma progression and metastasis through RAF / MEK signaling. Molecular Oncology. 17(7). 1324–1342. 2 indexed citations
7.
Almohanna, Mai, et al.. (2023). The curcumin analogue PAC has potent anti-anaplastic thyroid cancer effects. Scientific Reports. 13(1). 4217–4217. 5 indexed citations
8.
Al‐Sebayel, Mohammed, et al.. (2023). Sheep as a Model for Liver Transplantation. Cureus. 15(7). e42002–e42002.
9.
Al‐Dhfyan, Abdullah, Ayodele Alaiya, Falah Almohanna, et al.. (2022). Crosstalk between aryl hydrocarbon receptor (AhR) and BCL-2 pathways suggests the use of AhR antagonist to maintain normal differentiation state of mammary epithelial cells during BCL-2 inhibition therapy. Journal of Advanced Research. 50. 177–192. 8 indexed citations
10.
Zou, Minjing, Monther Al‐Alwan, Ibrahim Al‐Jammaz, et al.. (2021). β-Catenin Attenuation Inhibits Tumor Growth and Promotes Differentiation in a BRAFV600E-Driven Thyroid Cancer Animal Model. Molecular Cancer Therapeutics. 20(9). 1603–1613. 8 indexed citations
11.
Moghrabi, Walid, Latifa Al‐Haj, Maher Al‐Saif, et al.. (2021). Kinome inhibition reveals a role for polo‐like kinase 1 in targeting post‐transcriptional control in cancer. Molecular Oncology. 15(8). 2120–2139. 10 indexed citations
12.
Al-Jomah, Naif A., Falah Almohanna, & Abdelilah Aboussekhra. (2021). Tocilizumab suppresses the pro-carcinogenic effects of breast cancer-associated fibroblasts through inhibition of the STAT3/AUF1 pathway. Carcinogenesis. 42(12). 1439–1448. 24 indexed citations
13.
Almohanna, Falah, et al.. (2019). Estimating transfection efficiency in differentiated and undifferentiated neural cells. BMC Research Notes. 12(1). 225–225. 21 indexed citations
14.
Radwan, Awwad A., Falah Almohanna, Fars K. Alanazi, Pulicat Manogaran, & Abdullah Al‐Dhfyan. (2016). Target β-catenin/CD44/Nanog axis in colon cancer cells by certain N′-(2-oxoindolin-3-ylidene)-2-(benzyloxy)benzohydrazides. Bioorganic & Medicinal Chemistry Letters. 26(7). 1664–1670. 8 indexed citations
15.
Ghebeh, Hazem, Abdullah Al‐Dhfyan, Falah Almohanna, et al.. (2014). Fascin is involved in the chemotherapeutic resistance of breast cancer cells predominantly via the PI3K/Akt pathway. British Journal of Cancer. 111(8). 1552–1561. 64 indexed citations
16.
17.
Bouchama, Abderrezak, Falah Almohanna, Lina Assad, et al.. (2011). Tissue factor/factor VIIa pathway mediates coagulation activation in induced-heat stroke in the baboon. Critical Care Medicine. 40(4). 1229–1236. 47 indexed citations
18.
Almohanna, Falah, et al.. (2010). Dual Targeting of Retinal Vasculature: YC-1 Selectively Mediates Retinal Vascular Remodeling in the Ischemic Retina and Exhibits Potent Inhibitory Effects on Retinal Neovascularization in a Mouse Model of OIR. Investigative Ophthalmology & Visual Science. 51(13). 5906–5906. 1 indexed citations
19.
Almohanna, Falah, et al.. (2009). Pleiotropic Effects of YC-1 Attenuates Pathological Retinal Neovascularization. Investigative Ophthalmology & Visual Science. 50(13). 41–41. 2 indexed citations
20.
Alsmadi, Osama, et al.. (2009). Modulating the hypoxia-inducible factor signaling pathway as a therapeutic modality to regulate retinal angiogenesis. Experimental Eye Research. 89(5). 700–717. 31 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Annalisa Camporeale Breakdown of academic impact, for papers by Roberta Giuliani Breakdown of academic impact, for papers by Orr Sharpe Breakdown of academic impact, for papers by Dai Katayose Breakdown of academic impact, for papers by Zhentao Yang Breakdown of academic impact, for papers by Chi Sun Breakdown of academic impact, for papers by Nhat‐Tu Le Breakdown of academic impact, for papers by Jeremy A. Meier Breakdown of academic impact, for papers by Geraldine Gueron Breakdown of academic impact, for papers by Tracy L. Deem
Rankless by CCL
2026